busulfan
Also known as Busulfex IV®, Myleran®, Tetramethylene bis(methanesulfonate), 1,4-Dimesyloxybutane, 1,4-Bis(methanesulfonoxy)butane, 1,4-Dimethanesulfonoxybutane, 1,4-Butanediol dimethanesulfonate
Busulfan (Myleran, GlaxoSmithKline, Busulfex IV, Otsuka America Pharmaceutical, Inc.) is a chemotherapy drug in use since 1959. It is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical designation is 1,4-butanediol dimethanesulfonate.
Chemical data
- Formula
- C6H14O6S2
- Molecular weight
- 246.3 g/mol
- IUPAC name
- 4-methylsulfonyloxybutyl methanesulfonate
- SMILES
- CS(=O)(=O)OCCCCOS(=O)(=O)C
- InChIKey
- COVZYZSDYWQREU-UHFFFAOYSA-N
- XLogP
- -0.5
- Polar surface area
- 104 Ų
- H-bond donors
- 0
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
7,971 papersArticle
10 sectionsContents
- History
- Indications
- Availability
- Side effects
- Dosing, administration, and pharmacokinetics
- Drug interactions
- Pharmacology
- Complexation
- References
- External links
Busulfan (Myleran, GlaxoSmithKline, Busulfex IV, Otsuka America Pharmaceutical, Inc.) is a chemotherapy drug in use since 1959. It is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical designation is 1,4-butanediol dimethanesulfonate.
==History== Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost.